| Name | Orthomedical, Inc |
|---|---|
| Organization Name | Orthomedical, Inc |
| Location | 373 W Hwy 39, Ste 2, Blackfoot, Idaho 83221 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (208) 785-4595 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
RedHill Biopharma Ltd., an Israeli biopharmaceutical company focusing primarily on development and acquisition of late clinical stage, patent-protected, new formulations and combinations of existing drugs, reported the completion of a private placement in a total amount of approximately $6.5 million.
New research by scientists at Switzerland's Institute for Environmental Decisions reports that risk perception and public acceptance of NPIs depends on both worldview and levels of social trust. The study also found that, paradoxically, when the number of cases decreased in the period between the first and second waves, public willingness to comply with these measures fell.
Relypsa, Inc., a biopharmaceutical company developing non-absorbed polymeric drugs, today announced positive results from the company's PEARL-HF study, a Phase 2 clinical trial of the company's lead compound, RLY5016. These data were presented by Dr. Bertram Pitt, Professor of Medicine Emeritus, Division of Medicine at the University of Michigan School of Medicine, during the Late-Breaking Clinical Trials Session in an oral presentation titled "The PEARL-HF (Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple-Dose To Evaluate the Effects of RLY5016 in Heart Failure Patients) Trial" at the 14th Annual Scientific Meeting of the Heart Failure Society of America held in San Diego, CA September 13-15, 2010.
The relevance of positron emission tomography (PET) alone or in combination with computed tomography (CT) in patients with malignant melanoma cannot be currently assessed due to a lack of meaningful studies. This is the result of a final report published by the German Institute for Quality and Efficiency in Health Care (IQWiG) on 20 July 2011.
› Verified 4 days ago
| NPI Number | 1366517450 |
| Organization Name | ORTHOMEDICAL, INC |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 1053 W Bridge St, Blackfoot, ID 83221 |
| Phone Number | 208-785-4595 |
News Archive
RedHill Biopharma Ltd., an Israeli biopharmaceutical company focusing primarily on development and acquisition of late clinical stage, patent-protected, new formulations and combinations of existing drugs, reported the completion of a private placement in a total amount of approximately $6.5 million.
New research by scientists at Switzerland's Institute for Environmental Decisions reports that risk perception and public acceptance of NPIs depends on both worldview and levels of social trust. The study also found that, paradoxically, when the number of cases decreased in the period between the first and second waves, public willingness to comply with these measures fell.
Relypsa, Inc., a biopharmaceutical company developing non-absorbed polymeric drugs, today announced positive results from the company's PEARL-HF study, a Phase 2 clinical trial of the company's lead compound, RLY5016. These data were presented by Dr. Bertram Pitt, Professor of Medicine Emeritus, Division of Medicine at the University of Michigan School of Medicine, during the Late-Breaking Clinical Trials Session in an oral presentation titled "The PEARL-HF (Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple-Dose To Evaluate the Effects of RLY5016 in Heart Failure Patients) Trial" at the 14th Annual Scientific Meeting of the Heart Failure Society of America held in San Diego, CA September 13-15, 2010.
The relevance of positron emission tomography (PET) alone or in combination with computed tomography (CT) in patients with malignant melanoma cannot be currently assessed due to a lack of meaningful studies. This is the result of a final report published by the German Institute for Quality and Efficiency in Health Care (IQWiG) on 20 July 2011.
› Verified 4 days ago
News Archive
RedHill Biopharma Ltd., an Israeli biopharmaceutical company focusing primarily on development and acquisition of late clinical stage, patent-protected, new formulations and combinations of existing drugs, reported the completion of a private placement in a total amount of approximately $6.5 million.
New research by scientists at Switzerland's Institute for Environmental Decisions reports that risk perception and public acceptance of NPIs depends on both worldview and levels of social trust. The study also found that, paradoxically, when the number of cases decreased in the period between the first and second waves, public willingness to comply with these measures fell.
Relypsa, Inc., a biopharmaceutical company developing non-absorbed polymeric drugs, today announced positive results from the company's PEARL-HF study, a Phase 2 clinical trial of the company's lead compound, RLY5016. These data were presented by Dr. Bertram Pitt, Professor of Medicine Emeritus, Division of Medicine at the University of Michigan School of Medicine, during the Late-Breaking Clinical Trials Session in an oral presentation titled "The PEARL-HF (Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple-Dose To Evaluate the Effects of RLY5016 in Heart Failure Patients) Trial" at the 14th Annual Scientific Meeting of the Heart Failure Society of America held in San Diego, CA September 13-15, 2010.
The relevance of positron emission tomography (PET) alone or in combination with computed tomography (CT) in patients with malignant melanoma cannot be currently assessed due to a lack of meaningful studies. This is the result of a final report published by the German Institute for Quality and Efficiency in Health Care (IQWiG) on 20 July 2011.
› Verified 4 days ago
Lincare Inc Type: Durable Medical Equipment & Medical Supplies Supplier Location: 90 W Judicial St, Blackfoot, Idaho 83221 Phone: (208) 785-1571 | |
Walmart Pharmacy 10-1905 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 565 Jensen Grove Dr, Blackfoot, Idaho 83221 Phone: (208) 785-0277 | |
Norco Inc Type: Durable Medical Equipment & Medical Supplies Supplier Location: 1350 Parkway Dr, Blackfoot, Idaho 83221 Phone: (208) 782-0456 | |
Walgreens #13672 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 960 W Bridge St, Blackfoot, Idaho 83221 Phone: (208) 785-8000 | |
Orthomedical, Inc Type: Durable Medical Equipment & Medical Supplies Supplier Location: 373 W Hwy 39, Blackfoot, Idaho 83221 Phone: (208) 785-4595 |